HUP0002521A2 - A paclitaxel ónium sói, eljárás előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények - Google Patents

A paclitaxel ónium sói, eljárás előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0002521A2
HUP0002521A2 HU0002521A HUP0002521A HUP0002521A2 HU P0002521 A2 HUP0002521 A2 HU P0002521A2 HU 0002521 A HU0002521 A HU 0002521A HU P0002521 A HUP0002521 A HU P0002521A HU P0002521 A2 HUP0002521 A2 HU P0002521A2
Authority
HU
Hungary
Prior art keywords
paclitaxel
onium salts
medicaments
producing
same
Prior art date
Application number
HU0002521A
Other languages
English (en)
Inventor
George Digenis
Kenneth H. Kortright
Original Assignee
Baker Norton Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharmaceuticals, Inc. filed Critical Baker Norton Pharmaceuticals, Inc.
Publication of HUP0002521A2 publication Critical patent/HUP0002521A2/hu
Publication of HUP0002521A3 publication Critical patent/HUP0002521A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A paclitaxel új 2'-ónium-sói emlősökön prodrugként hatnak miközben invivo paclitaxel keletkezik. A találmány ilyen óniumsókra éselőállítási eljárásukra vonatkozik; továbbá az új sókat tartalmazógyógyászati készítményekre, melyek alkalmasak paclitaxel terápiáraszoruló betegeknek való beadásra. Ó
HU0002521A 1997-06-20 1997-06-20 Onium salts of paclitaxel, process for producing them and medicaments comprising the same HUP0002521A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/010746 WO1998058927A1 (en) 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel

Publications (2)

Publication Number Publication Date
HUP0002521A2 true HUP0002521A2 (hu) 2001-06-28
HUP0002521A3 HUP0002521A3 (en) 2002-04-29

Family

ID=22261122

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002521A HUP0002521A3 (en) 1997-06-20 1997-06-20 Onium salts of paclitaxel, process for producing them and medicaments comprising the same

Country Status (10)

Country Link
EP (1) EP1001769B1 (hu)
JP (1) JP2002505682A (hu)
AT (1) ATE219363T1 (hu)
AU (1) AU3574097A (hu)
CA (1) CA2294606A1 (hu)
DE (1) DE69713526D1 (hu)
HU (1) HUP0002521A3 (hu)
IL (1) IL133585A0 (hu)
SK (1) SK182599A3 (hu)
WO (1) WO1998058927A1 (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
WO2002064132A2 (en) * 2001-01-18 2002-08-22 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060188508A1 (en) 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
JP5523313B2 (ja) 2007-07-03 2014-06-18 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用
WO2009143454A2 (en) 2008-05-22 2009-11-26 Kereos, Inc. Combination antitumor therapy
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
ES2779225T3 (es) * 2011-04-08 2020-08-14 Sphaera Pharma Pte Ltd Reactivos de merilformilo sustituido y procedimiento de uso de los mismos para modificar propiedades fisicoquímicas y/o farmacocinéticas de compuestos
JP6578206B2 (ja) 2012-07-19 2019-09-18 レッドウッド バイオサイエンス， インコーポレイテッド Ｃｄ２２に特異的な抗体およびその使用方法
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
SI3613439T1 (sl) 2013-02-15 2021-11-30 The Regents Of The University Of California Himerni antigenski receptor in postopki njegove uporabe
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
US9493413B2 (en) 2013-11-27 2016-11-15 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP3107899B1 (en) 2014-02-19 2020-08-12 Aviv Therapeutics, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
US20210206826A1 (en) 2015-11-19 2021-07-08 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
EP3231421A1 (en) 2016-04-11 2017-10-18 Greenaltech, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
EP3463308B1 (en) 2016-06-01 2021-12-01 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
MX2019008503A (es) 2017-01-18 2019-09-13 F1 Oncology Inc Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CN111902147A (zh) 2018-01-31 2020-11-06 加莱拉实验室有限责任公司 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗
CA3096838A1 (en) 2018-04-11 2019-10-17 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CA3131895A1 (en) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CN115023443A (zh) 2020-01-29 2022-09-06 肯乔克蒂生物技术股份有限公司 抗mdr1抗体及其用途
JP2023528416A (ja) 2020-06-04 2023-07-04 ケンジョッケティ バイオテクノロジー，インク． 抗ａｂｃｇ２抗体及びそれらの使用
US20230192902A1 (en) 2020-06-04 2023-06-22 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
WO2022051390A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
WO2022103603A1 (en) 2020-11-13 2022-05-19 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
WO2023114658A1 (en) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053811A1 (en) * 1997-05-27 1998-12-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
WO1997015571A1 (en) * 1995-10-27 1997-05-01 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs

Also Published As

Publication number Publication date
SK182599A3 (en) 2000-07-11
AU3574097A (en) 1999-01-04
EP1001769A1 (en) 2000-05-24
CA2294606A1 (en) 1998-12-30
WO1998058927A1 (en) 1998-12-30
IL133585A0 (en) 2001-04-30
ATE219363T1 (de) 2002-07-15
EP1001769A4 (en) 2000-05-24
EP1001769B1 (en) 2002-06-19
JP2002505682A (ja) 2002-02-19
DE69713526D1 (de) 2002-07-25
HUP0002521A3 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
HUP0002521A2 (hu) A paclitaxel ónium sói, eljárás előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
KR950703968A (ko) 외상 손상과 관련된 신경학적 병변의 치료에서 카르바마제핀 및 옥스카르바제핀의 적용(application of carbamazepine and oxcarbazepine in the treatment of neurological lesions related to traumatic injuries)
CY1107391T1 (el) Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
ES2167608T3 (es) Composicion basada en monoxido de nitrogeno como medicamento.
AR020662A1 (es) Compuestos dihidrotiazoles policiclicos, procedimientos para su preparacion, medicamento, procedimiento para la preparacion de dicho medicamento y lautilizacion de dichos compuestos para la preparacion de un medicamento.
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
BR0106851A (pt) Mistura de conjugados, composição farmacêutica, método de tratar deficiência de insulina em um indivìduo com necéssidade de tal tratamento e processo para sintetizar uma mistura de conjugados
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
ATE238038T1 (de) Liposomale formulierungen von mitoxantron
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
HUP0203198A2 (hu) Tramadolvegyület és görcsoldó hatóanyagot tartalmazó gyógyászati készítmény, eljárás az előállítására és alkalmazása
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
IL112664A (en) 4-amino derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
ATE332702T1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
IL112667A (en) 6-substituted derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
ATE219670T1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
ATE123944T1 (de) Verwendung von trifluormethylphenyl- tetrahydropyridinen zur herstellung von arzneimitteln zur behandlung anxio-depressiver erkrankungen.
ATE173626T1 (de) Verwendung eines ascorbyl-tocopherylphosphats zur herstellung eines arzneimittels zur behandlung der pankreatitis
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
DE69005860D1 (de) Verwendung von 5'-Deoxy-5'-methylthioadenosin S-adenosylmethionin und dessen Salzen zur Herstellung von Seborrhea vermindernden Arzneimitteln.
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
MX9800622A (es) Agentes terapeuticos mejorados.